论文部分内容阅读
目的探讨布地奈德联合沙丁胺醇治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法选择医院收治的AECOPD患者50例,随机分为A组和B组,每组25例。A组在常规治疗的基础上加用布地奈德雾化吸入,B组在常规治疗的基础上加用布地奈德联合沙丁胺醇雾化吸入,治疗7d后,检测2组C反应蛋白(CRP)和白介素(IL)的浓度,比较2组临床疗效及COPD评估测试(CAT)评分。结果 B组IL-6、IL-8、IL-13、IL-17、CRP浓度和CAT评分均低于A组,IL-10浓度和总有效率均高于A组,差异有统计学意义(P<0.05和P<0.01)。结论布地奈德联合沙丁胺醇治疗AECOPD效果满意,能有效降低AECOPD患者CRP和IL浓度。
Objective To investigate the clinical efficacy of budesonide combined with albuterol in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Fifty patients with AECOPD admitted to hospital were randomly divided into A group and B group, with 25 cases in each group. Group A was treated with budesonide inhalation on the basis of conventional treatment. Group B was inhaled with budesonide combined with salbutamol on the basis of conventional treatment. After treatment for 7 days, two groups of CRP and Interleukin (IL) levels were compared between the two groups of clinical efficacy and COPD assessment test (CAT) score. Results The concentrations of IL-6, IL-8, IL-13, IL-17, CRP and CAT in group B were lower than those in group A, and the concentration and total effective rate of IL-10 in group B were significantly higher than those in group A P <0.05 and P <0.01). Conclusions Budesonide combined with salbutamol treatment of AECOPD satisfactory results, can effectively reduce the AECOPD patients with CRP and IL concentrations.